The resurgence of interest in hepatitis B and the many novel antiviral and immune modulatory therapies in development or early phase clinical trials has led to many questions. This comprehensive workshop will bring together academic investigators, regulatory agencies, and the pharmaceutical industry to discuss how we assess the efficacy and safety of these therapies, and how we determine the appropriate trial designs and endpoints for testing these therapies. Consensus from this workshop will provide answers to these questions and create a blueprint that may lead to a cure for hepatitis B and D.
AASLD and EASL welcome your abstract submissions for the HBV Treatment Endpoints Workshop. It is critical to develop innovative research as we propel the field of hepatology and pursue a cure for hepatitis B. Don't miss this opportunity to share your research with your peers and other key stakeholders while contributing to the next steps in eliminating hepatitis B.
The American Association for the Study of Liver Diseases (AASLD) &
The European Association for the Study of the Liver (EASL)